ASCO GU 2021: Pembrolizumab for the Treatment of Patients with High-Risk Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Gurin: Extended Follow-up of KEYNOTE-057 Cohort A
"Overall, 101 patients received pembrolizumab and 96 were included in the efficacy analysis (five patients did not meet BCG-unresponsive criteria). The median age of patients was 73 years (range: 44-92), and patients received a median of 12.0 (range: 7.0-45.0) BCG instillations. In this updated analysis, the median time from enrollment to data cutoff date of May 25, 2020, was 36.4 months (range: 26.3-48.5). Of 96 patients, the complete response rate was 40.6% (95% confidence interval [CI] 30.7-51.1) at first evaluable disease assessment, and the median duration of response was 16.2 months (range: 0.0+ to 36.2). Among 39 responders, 13 (33.3%) remained in complete response ≥18 months and 9 (23.1%) remained in complete response ≥24 months as of the data cutoff date"
Keytruda CR summary:
CR @ first evaluable assessment = 40.6%
Maintained CR @ 12(+) months = 19%
Maintained CR @ 18(+) months = 13.5%
Maintaned CR @ 24(+) months = 9.4%
Re: CR, a relatively low bar has been set...one that is getting significantly lower with time.
Add in number of required treatments, treatment compliance & overall cost, that bar drops even further. All imo...GLTA.